GLP-1 Agonists: Semaglutide vs Tirzepatide vs Retatrutide
GLP-1 receptor agonists have transformed the weight management and metabolic health landscape. Semaglutide (Ozempic®/Wegovy®) was the breakthrough, Tirzepatide (Mounjaro®/Zepbound®) raised the bar with dual-agonism, and Retatrutide represents the next frontier as a triple agonist. All three reduce appetite and improve metabolic markers, but they differ meaningfully in mechanism, efficacy magnitude, side effect profiles, and regulatory status. This comparison helps you understand the evolving landscape.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.
| Category | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Drug Class | GLP-1 receptor agonist (single agonist) | GIP/GLP-1 dual receptor agonist (twincretin) | GIP/GLP-1/Glucagon triple receptor agonist |
| FDA Status | FDA-approved for T2D (Ozempic®) and obesity (Wegovy®) | FDA-approved for T2D (Mounjaro®) and obesity (Zepbound®) | Phase III trials (not yet FDA-approved) |
| Mechanism | Activates GLP-1 receptors → insulin secretion, appetite suppression, delayed gastric emptying | Activates both GIP and GLP-1 receptors → enhanced insulin response, greater appetite suppression, improved fat metabolism | Activates GIP, GLP-1, and glucagon receptors → appetite suppression + increased energy expenditure + enhanced fat oxidation |
| Average Weight Loss (Trials) | ~15–17% body weight (STEP trials, 68 weeks) | ~20–22.5% body weight (SURMOUNT trials, 72 weeks) | ~24% body weight (Phase II, 48 weeks at highest dose) |
| Effect on HbA1c | −1.5–1.8% (strong glycemic control) | −2.0–2.4% (superior glycemic control) | −2.0%+ (early data, comparable to tirzepatide) |
| Cardiovascular Benefits | Proven MACE reduction (SELECT trial) — 20% risk reduction | CV outcomes trial (SURPASS-CVOT) ongoing; positive signals | Too early — no CV outcomes data yet |
| Dosing Schedule | Once weekly subcutaneous injection (0.25–2.4 mg) | Once weekly subcutaneous injection (2.5–15 mg) | Once weekly subcutaneous injection (dose-finding ongoing) |
| GI Side Effects | Common: nausea (44%), diarrhea (30%), vomiting (24%) | Common but generally milder: nausea (31%), diarrhea (23%), vomiting (12%) | Similar to semaglutide; nausea, diarrhea, vomiting at higher doses |
| Muscle Mass Preservation | ~25–40% of weight lost is lean mass (a concern) | Better lean mass preservation than semaglutide in head-to-head data | Glucagon component may enhance fat-selective weight loss (early signal) |
| Effect on Liver Fat (MASLD) | Significant reduction in liver fat (∓65–70%) | Superior liver fat reduction vs semaglutide in SYNERGY-NASH | Glucagon receptor activation may provide additional hepatic benefit |
| Unique Advantage | Longest track record, proven CV benefit, widest availability | Greater weight loss, better GI tolerability, superior glycemic control | Triple mechanism may offer highest efficacy and metabolic benefit |
| Key Limitation | Lower ceiling of weight loss vs newer agents; GI side effects | Higher cost; supply constraints; less long-term safety data than semaglutide | Not yet approved; Phase III ongoing; limited long-term data |
| Cost (US, approximate) | ~$1,000–$1,350/month (brand); compounded versions available | ~$1,000–$1,200/month (brand); compounded versions emerging | Not yet commercially available |
Summary
The GLP-1 agonist landscape is evolving rapidly. Semaglutide remains the gold standard with the deepest evidence base — it has proven cardiovascular benefit (SELECT trial), extensive long-term safety data, and the widest global availability. Tirzepatide has emerged as a more potent option, delivering ~5–7% greater weight loss in head-to-head comparisons (SURMOUNT-5), with generally better GI tolerability thanks to its dual GIP/GLP-1 mechanism. The GIP component appears to buffer against some of the nausea that pure GLP-1 agonism causes. Retatrutide represents the next generation — its triple agonism adds glucagon receptor activation, which increases energy expenditure and fat oxidation beyond what GLP-1 alone achieves. Phase II data showing ~24% weight loss at 48 weeks is remarkable, though Phase III results and long-term safety data are still pending. For most patients today, the choice between semaglutide and tirzepatide depends on insurance coverage, availability, tolerability, and the degree of weight loss needed. Retatrutide may redefine the field once approved, but it remains investigational. All three should be used under medical supervision as part of a comprehensive metabolic health plan that includes nutrition, exercise, and ongoing monitoring.
These peptides are often used together. See our stack profiles for combination details.